HIV Archives | Be Korea-savvy
Wistar Institute HIV Researchers Win Grant to Explore Genetically Engineered Natural Killer Cells as HIV Therapy

Wistar Institute HIV Researchers Win Grant to Explore Genetically Engineered Natural Killer Cells as HIV Therapy

PHILADELPHIA, PA, Jan. 19 (Korea Bizwire) — amfAR, The Foundation for AIDS Research, has awarded Luis J. Montaner, D.V.M., D.Phil., in collaboration with Mohamed Abdel-Mohsen, Ph.D., a Target Grant for $397,663 over two years. Montaner, who leads The Wistar Institute’s HIV Research Program, is studying the ability of a type of immune cell known as natural killer (NK) cells [...]

Reports of HIV Infection Fall Drastically in Post-COVID Era

Reports of HIV Infection Fall Drastically in Post-COVID Era

SEOUL, Aug. 22 (Korea Bizwire) — The number of people living in South Korea that have tested positive for human immunodeficiency virus (HIV) have drastically fallen since the coronavirus outbreak, primarily due to the suspension of HIV-exclusive testing programs and anonymous examinations at most public health clinics, a report said Sunday. The Korea Disease Control [...]

Sustained Efficacy of Long-Acting Cabotegravir for PrEP Among Cisgender Women – Findings from HPTN 084 Study

Sustained Efficacy of Long-Acting Cabotegravir for PrEP Among Cisgender Women – Findings from HPTN 084 Study

DURHAM, N.C., July 28 (Korea Bizwire) — Researchers from the HIV Prevention Trials Network (HPTN) presented updated results from the HPTN 084 long-acting cabotegravir (CAB) for pre-exposure prophylaxis (PrEP) study at the AIDS 2022 conference in Montreal. New findings show reductions in HIV incidence were sustained in the 12 months following trial unblinding (November 5, 2020, through [...]

HPTN Studies Inform FDA’s Approval of ViiV Healthcare’s Long-Acting Cabotegravir Injections for HIV Prevention

HPTN Studies Inform FDA’s Approval of ViiV Healthcare’s Long-Acting Cabotegravir Injections for HIV Prevention

DURHAM, N.C., Dec. 21 (Korea Bizwire) — Data from the HIV Prevention Trials Network (HPTN) studies HPTN 083 and HPTN 084 helped provide important information for yesterday’s decision by the U.S. Food and Drug Administration (FDA) to approve ViiV Healthcare’s long-acting cabotegravir (CAB-LA) injections for the prevention of HIV. Sponsored and co-funded by the National [...]

Health Authorities Publish Guidelines on HIV Treatment

Health Authorities Publish Guidelines on HIV Treatment

SEOUL, Dec. 4 (Korea Bizwire) — The Korea Disease Control and Prevention Agency announced Thursday that new guidelines on treating human immunodeficiency virus (HIV) patients have been published. The guide includes eight recommendations for the healthcare workers, caretakers, and other related personnel. On the patient’s right to health, the guide proclaims that all patients have [...]

HIV Prevention Trials Network Awarded U.S. National Institutes of Health Funding to Continue Research Agenda

HIV Prevention Trials Network Awarded U.S. National Institutes of Health Funding to Continue Research Agenda

DURHAM, N.C., Nov. 30 (Korea Bizwire) — Drs. Myron S. Cohen and Wafaa M. El-Sadr, principal investigators of the HIV Prevention Trials Network (HPTN), in collaboration with FHI 360, have received a seven-year award from the U.S. National Institutes of Health as part of the next funding cycle (2020-2027) for the Network. The core and [...]

HPTN 084 Study Demonstrates Superiority of CAB LA to Oral FTC/TDF for the Prevention of HIV

HPTN 084 Study Demonstrates Superiority of CAB LA to Oral FTC/TDF for the Prevention of HIV

Durham, N.C., Nov. 9 (Korea Bizwire) — Researchers from the HIV Prevention Trials Network (HPTN) announced today data from the HPTN 084 clinical trial indicate that a pre-exposure prophylaxis (PrEP) regimen of long-acting cabotegravir (CAB LA) injections once every eight weeks was safe and superior to daily oral tenofovir/emtricitabine (FTC/TDF) for HIV prevention among cisgender women in sub-Saharan Africa. During a planned review of study data, an independent Data and Safety Monitoring Board (DSMB) recommended the study sponsor―the National Institute of Allergy and Infectious Diseases [...]

Same-sex Sexual Contact Primary Driver of HIV Infections in S. Korea

Same-sex Sexual Contact Primary Driver of HIV Infections in S. Korea

SEOUL, July 15 (Korea Bizwire) — The number of people who are infected with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) through same-sex sexual contact is gradually increasing in South Korea. Among those who were infected with HIV or AIDS last year through sexual contact, more than half of them were infected through [...]